RGD Reference Report - The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.

Authors: Shen, Lei  Shi, Hong  Gao, Yan  Ou, Qinfang  Liu, Qianqian  Liu, Yuanyuan  Wu, Jing  Zhang, Wenhong  Fan, Lin  Shao, Lingyun 
Citation: Shen L, etal., Tuberculosis (Edinb). 2016 Dec;101:146-150. doi: 10.1016/j.tube.2016.10.001. Epub 2016 Oct 1.
RGD ID: 41412174
Pubmed: PMID:27865385   (View Abstract at PubMed)
DOI: DOI:10.1016/j.tube.2016.10.001   (Journal Full-text)

PD-1 is a cell surface receptor of activated T and B lymphocytes and it's role in tuberculosis is controversial because of lack of congruence between clinical study and animal model. To investigate the immunological pathogenesis mechanisms of tuberculosis and to develop the immune therapy target essential for controlling tuberculosis, here we explored the expression characteristics and dynamic changes of PD-1/PD-L1 pathway in different CD4+T cell subsets. We enrolled 24 human subjects including 15 active tuberculosis (ATB) patients and 9 healthy donors (HD). The expressions of PD-1 and PD-L1 on CD4+T cells increased significantly in ATB patients than HD. ATB patients had a higher proportion of regulatory T cells (Treg, CD4+CD25 + Foxp3+) than HD. The expressions of PD-1 and PD-L1 increased remarkably on CD4+T cell subsets, including Treg cells, Tresp (CD4+CD25-) cells and Teff (CD4+CD25 + Foxp3-) cells. Finally, clinical improvement following effective anti-TB therapy is correlated with significantly decreased expression of PD-1 in Tresp and Teff cells, but not in Treg cells. Thus, expression profiles of PD-1 in T cell subpopulations may be used as a candidate to predict the clinical efficacy of anti-tuberculosis therapy. Modulation of PD-1/PD-L1 pathway in CD4 subsets may offer an immunotherapy target for the control of tuberculosis.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
PDCD1Humantuberculosis treatmentIEP  RGD 
Pdcd1Rattuberculosis treatmentISOPDCD1 (Homo sapiens) RGD 
Pdcd1Mousetuberculosis treatmentISOPDCD1 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Pdcd1  (programmed cell death 1)

Genes (Mus musculus)
Pdcd1  (programmed cell death 1)

Genes (Homo sapiens)
PDCD1  (programmed cell death 1)


Additional Information